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The influence of 10-‘“-10-6 M morphine on the release of [‘Hlarachidonic acid and its metabolites #H]AAM) from prelabeled resident peritoneal 
murme macrophages was investigated. Morphine enhanced [‘H]AAM release from A231 87- and LPS-stimulated macrophages, as well as the basal 
release of [3H]AAM. Dose-response curves showed a maximum at lo-’ M morphine. Naloxone had no effect on morphme enhancement of 
[SH]AAM release. These results are in agreement with the hypothesis that [‘H]AAM may be involved m the effects of morphine. 
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1. INTRODUCTION 
The mechanism for the inter-relationship between 
opioids and prostaglandins is one of the most fascinat- 
ing problems in biochemistry. As early as 1969 Jagues 
reported that analgesic drugs of both the morphine and 
aspirin groups inhibit the contraction of the longitudi- 
nal muscle of isolated guinea-pig ileum, elicited by ara- 
chidonic acid (AA) [l]. Since then the problem has been 
much studied, and many investigators have amassed a 
convincing body of evidence that opioid ligands influ- 
ence the effects of prostaglandins, acyclooxygenase me- 
tabolite of AA [2-51. Morphine has been shown to in- 
hibit, in many tissues, the effects of prostaglandins [2,3] 
but stimulate their synthesis [4,5]. The relationship be- 
tween opioid ligands and prostaglandins, however, has 
not been studied in cells of the immune system. 
The influence of opioid peptides and opioids, like 
morphine, on the immune and defence functions are 
under intensive investigation. These substances, intro- 
duced in vivo, change various immune functions [6]. On 
the other hand, AA metabolism has been reported as a 
factor which modulates cell functions involved in vari- 
ous immunological and inflammatory phenomena [7]. 
In addition, macrophages isolated from morphine-de- 
pendent rats enhanced their release of prostaglandins 
[S]. The surprising thing is that a direct effect of mor- 
phine on the release of AA and its metabolites is as yet 
unknown. 
Over several years we have been investigating ex- 
ogenous and endogenous regulators of eicosanoid syn- 
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thesis [9,10]. In addition we have studied opioid recep- 
tors on different cell systems [11,12]. The aim of the 
present work was to study the in vitro effect of mor- 
phine on the release of AA and its metabolites from 
resident peritoneal macrophages. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
Mice were killed by cervical dislocation between 15.00-16.00 h m 
order to take into account possible circadian changes and their influ- 
ence on macrophage function. Resident macrophages were obtained 
by peritoneal lavage of untreated F,-mice with sterile Dulbecco’s mod- 
ified Eagle’s medium (DMEM). Cells were counted, then 2 x lo6 cells/ 
ml were suspended in DMEM with 10% heat-inactivated fetal calf 
serum, L-glutamine (2 mM) and 100 U gentamicm. The viability of 
these cells, as Judged by Trypan blue exclusion, was never below 96%. 
The suspension (3 ml) was dispensed onto 6-wells culture dishes at 
37°C m humidified air containing 5% COz. After 2 h preincubation, 
non-adherent cells were removed by washing with the medium, the 
adherent cells were supplemented with fresh medium and Incubated 
for 12-16 h at 37°C in humidified air, containing 5% CO1 before 
experiments in order to adapt cells to post-isolation conditions. 
2.2 Release qf /jHJAA und IO metabolites from labelled macrophages 
Macrophages were cultured in 6-well dishes m fresh DMEM supple- 
mented with 1% bovine serum albumin (BSA) and with the addition 
of 25 nCi of [‘H]AA. After 4 h the macrophages were washed three 
times with DMEM to remove unincorporated radiolabel then incu- 
bated for 2 h in DMEM with 1% BSA. The initial time was time of 
addition of tested ligands and stimulators, A23187 (Sigma) or LPS 
(Difco). Final concentrations of stimulators were 5 PM and 25 &ml, 
respectively. At that time 200 ~1 of the medium were removed and the 
radioactivity determined by scmtillation counting. 
2.3. Datu processing 
The in vitro effect of morphine was investigated in 8 independent 
experiments. For each experiment macrophages were pooled from 8 
mice. Each point of radioactivity release was duplicated. The results 
were processed using the Sigmaplot ~4.0 program (Jandel Scientific) 
on an IBM PC. 
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Fig. 1, Kinetics of morphine influence on basal [3H]AAM release from 
peritoneal murine macrophages. Morphme concentration: I. 10s6 M: 
2, lo-” M; 3, lo-” M; 4. without morphine. 
3. RESULTS 
We showed that morphine exerted direct action on 
peritoneal macrophages. Morphine enhanced the re- 
lease of the [3H]AAM from non-stimulated and LPS- 
and A23 187-stimulated peritoneal macrophages. 
To investigate the influence of opioid ligands on en- We revealed a bell-shaped dependence of morphine 
dogenous AA metabolism in macrophages we measured effect on the stimulated AAM release with a maximum 
the radioactivity release from [3H]AA-prelabeled cells. at 10d8 M morphine. These results may account for the 
This is the usual method of evaluation of release from absence of the direct influence of morphine on rat mac- 
cells of AA and its metabolites [13,14]. The detected rophages when 1 O-” M opioid ligands are used [S]. Mor- 
values constituted the total, [IH]AA plus [“HIAA-me- phine was less effective on [jH]AAM release at a con- 
tabolite, radioactivity, named hereafter [3H]AAM. centration of 10eh M than at lo-“’ or lo-’ M. This fact 
Fig. 1 (curve 1) demonstrates a slight basal release of is not surprising as similar results have been found in 
[3H]AAM from macrophages. Exposure of [‘H]AA-la- 
beled cells to morphine resulted in the dose-dependent 
release of [3H]AAM from membrane phospholipids. 
Morphine at a concentration of 10-6-10-‘u M signifi- 
cantly enhanced this release (curves 24). The maximal 
enhancement corresponded to IO-’ M morphine. 
The doseeresponse curves for the enhancement of the 
A23 187-induced [jH]AAM release by morphine re- 
vealed a bell-shaped dependence as well. Maximal re- 
lease corresponded to lo-” M morphine but 10eh M 
morphine had only a slight effect (Fig. 9). 
Morphine also enhanced the [3H]AAM release with 
lipopolysaccharide (LPS) as a stimulator (Fig. 3). The 
ratio of the effect of morphine plus stimulator to the 
effect of stimulator itself was remarkably greater for 
LPS as compared to A23187 (Fig. 3). Naloxone en- 
hanced the [3H]AAM release from the cells and did not 
abolish the morphine effect (Fig. 3). 
4. DISCUSSION 
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Fig. 2. Dose-response curves for the enhancement of A23 187-induced 
AAM release by morphme. All values have been corrected by sub- 
tracting the basal release of [jH]AAM. The values shown are the 
mean f S.E.M. [‘HIAAM released after 120 min of stimulatron and 
are expressed as a percentage of the [‘HIAAM release with A23187 
only. 
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Fig 3. Effect of IO-’ M morphme and IO-’ M naloxone on A23187- 
and LPS-induced [‘H]AAM release. All values have been corrected by 
substracting the basal release of [‘HIAAM. Bars represent 
mean k S.E.M. [‘H]AAM released after 120 min of atimulatton and 
correspond to (I 1 basal. (2) LPS only, (3) LPS and morphme. (4) 
A23187 only. (5) A23187 and morphme. (6) A23187. morphine and 
naloxone, (7) A231 87 and naloxone. 
164 
Volume 323, number 1,2 FEBSLETTERS May 1993 
the opioid peptide modulation of other immune para- 
meters [16,17]. 
Naloxone, which is regarded as a classical antagonist 
of opioid receptors, under our experimental conditions 
acted as an agonist of morphine, i.e. enhanced 
[3H]AAM release from cells and did not abolish the 
morphine effect. Specific opiate receptors have been 
demonstrated on mononuclear cells [ 181, as well as non- 
classical binding sites for opioid ligands [ 191. Our results 
confirm the suggestion [20,21] that naloxone can influ- 
ence some functions of the immune system unrelated to 
its opioid receptor antagonism. 
Stimulation of AA metabolism, along with other im- 
munosuppressive effects of morphine, can aid in sup- 
pressing the resistance of drug-dependent animals and 
people to infections, and also promote regulation of 
other functions of the immune system. The elucidation 
of the mechanism of morphine effect on different enzy- 
matic systems of AA metabolism is the subject of our 
further investigations. 
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